Latest News
Scribe Therapeutics Inc.
- Cathie Wood’s ARK sells Shopify stock, buys Scribe Therapeutics
- Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst
- Why Did Scribe Therapeutics (NASDAQ:SCTX) Fall 7% to USD 19.22?
- Scribe Therapeutics Inc. (NASDAQ:SCTX) Sees Significant Growth in Short Interest
- Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated "Moderate Buy" by Wall Street Analysts
- Scribe Surges On IPO Debut — But All Eyes Turn To 1H27 Data (NASDAQ:SCTX)
- Cathie Wood’s ARK adds to Scribe Therapeutics stock position
- Cathie Wood’s ARK sells Tempus AI stock, buys Scribe Therapeutics By Investing.com
- Tracking Cathie Wood: Adding Scribe and Beam in Gene Editing, Reducing Tempus AI
Headlines from the last 30 days, linking to the original publishers. See all market news →